Press Releases

August 22, 2024
Neuvivo Announces Mark Henderson, PhD, as Vice President of Manufacturing to Support Technical Operations for Investigational ALS Treatment

August 21, 2024
Neuvivo Appoints Matthew W. Davis, MD, RPh, as New Chief Medical Officer to Continue Advancing Novel ALS Treatment 

June 15, 2023
Neuvivo Raises $11M in Venture Financing to Develop Treatment for ALS

March 30, 2023
New Study of Neuvivo’s NP001 is First to Link Regulation of the Innate Immune System with Respiratory Function in ALS Patients

December 1, 2022
Neuvivo’s NP001 for Treatment of ALS Slows Disease Progression Through Regulation of Microbial Translocation

June 20, 2022
Neuvivo Adds Former FDA Chief Counsel Peter Barton Hutt as Advisor

June 2, 2022
Neuvivo’s NP001 – an Immune System Regulator – Has Effect on Biomarkers of Microbial Translocation in ALS Patients Responsive to Treatment

May 26, 2022
Neuvivo Closes on Additional Funding Round for NP001 Development

May 11, 2022
Neuvivo Begins Manufacturing of NP001 for Treatment of ALS

April 14, 2022
Neuvivo Announces Addition of Michael Snyder, PhD – Chair of the Department of Genetics at the Stanford School of Medicine – to Scientific Advisory Board

February 8, 2022
Neuvivo Adds James Kovach, MD, former NFL Player, and Current Executive Director of UC Davis Health Translational Entrepreneurship Program to Advisory Board

February 1, 2022
Neuvivo Announces Publication of Paper on ALS Drug Candidate NP001 in Peer-Reviewed Journal, Muscle & Nerve

January 5, 2022
Neuvivo Expands Management Team Adding Gregg Fergus, Former President of Ion Torrent, as Head of Strategy and Business Development and to the Board of Directors

December 16, 2021
Neuvivo Announces Filing of Type C Meeting Request with FDA Regarding Its Plans for Development and Marketing of NP001 for the Treatment of ALS

December 1, 2021
Neuvivo Launches to Develop and Market Effective and Safe Treatments for ALS

Publications

Respiratory Function Conservation in ALS is Potentially Linked to Modulation of the Innate Immune System, ENCALS 2023 Abstract 

  Regulation of the Innate Immune System as a Therapeutic Approach to Supporting Respiratory Function in ALS, Cells, March 28, 2023

 

Macrophage-Targeted Sodium Chlorite (NP001) Slows Progression of Amyotrophic Lateral Sclerosis (ALS) through Regulation of Microbial Translocation, Biomedicines, Nov 12, 2022

 

Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: pre-specified and post-hoc analysis Muscle & Nerve, Jan 31, 2022

 

Randomize Phase 2 Trial of NP001 – a Novel Immune Regulator: Safety and Early Efficacy in ALS, Neurology Neuroimmunology & Neuroinflammation, April 9, 2015

 

NP001 Regulation of Macrophage Activation Markers in ALS: A Phase I Clinical and Biomarker Study, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Dec 15, 2014